Detalles de la búsqueda
1.
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast Cancer Res
; 21(1): 39, 2019 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30867034
2.
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Breast Cancer Res Treat
; 171(1): 11-20, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29725889
3.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
BMC Cancer
; 18(1): 965, 2018 Oct 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30305055
4.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29146401
5.
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.
JAMA
; 317(6): 596-605, 2017 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28196254
6.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(3): 367-377, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26874901
7.
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Lancet Oncol
; 14(11): 1121-1128, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24007746
8.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Eur J Cancer
; 184: 48-59, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898233
9.
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Breast Cancer Res Treat
; 134(1): 333-43, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22538770
10.
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
JAMA
; 305(18): 1873-81, 2011 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-21558518
11.
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Clin Cancer Res
; 27(3): 807-818, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33122343
12.
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Clin Breast Cancer
; 21(1): 80-91.e7, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33183970
13.
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
Clin Breast Cancer
; 20(3): e251-e260, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32139271
14.
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Clin Cancer Res
; 26(23): 6149-6157, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32988969
15.
The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
Breast Cancer Res Treat
; 116(3): 521-7, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19139988
16.
Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer.
JCO Precis Oncol
; 3: 1-26, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35100698
17.
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
NPJ Breast Cancer
; 5: 36, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31667338
18.
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Clin Cancer Res
; 25(10): 2975-2987, 2019 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30723140
19.
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Clin Breast Cancer
; 8(6): 527-32, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19073509
20.
Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.
Anticancer Res
; 28(3B): 1733-40, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18630452